NCT04727723Completed
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Two Steps Italian Prospective obsErvationAL Study Assessing the Effectiveness and Outcomes Associated With LUtathera (177Lu) Oxodotreotide Treatment in Adult Subjects With Unresectable or Metastatic, Progressive, Well Differentiated (G1 and G2), Somatostatin Receptor Positive Gastroenteropancreatic-neuroendocrine Tumours (GEP-NETs) - REAL-LU
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 164 (actual)
- First submitted
- 20 Nov 2020
- Start date
- 9 Mar 2021
- Primary completion date
- 10 Mar 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT04727723
What you commit to
- Study type: Observational
- Participants enrolled: 164
- From 9 Mar 2021 to the primary completion date, 10 Mar 2026
- 18 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in a current or prior investigational study within 30 days preceding enrolment or within 5 half-lives of the investigational product, whichever is longer.
Who the study is looking for
- Written informed consent must be obtained prior to any data collection.
- Patients must be diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic-neuroendocrine tumour (GEP-NET).
- Aged ≥18 years.
- Patients must be naïve to treatment with Lutathera® at enrolment.
Age in the registry: 18 years to 100 years · Sex: All
Sites (18)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Alessandria | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Brescia | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Cona | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Latina | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Meldola | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Messina | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Naples | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Negrar | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Pisa | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Reggio Emilia | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Rionero in Volture | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Rozzano | Italy | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Torino | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.